Genitourinary Active and enrolling clinical trials Find out if your patients are eligible

GYNECOLOGIC CANCERS

DOSTARLIMAB FELADILIMAB Bintrafusp alfa (anti–PD-1 antibody) (ICOS agonist IgG4 antibody)† ± (bifunctional TGF-β “trap”/ DOSTARLIMAB, COBOLIMAB, anti–PD-L1 fusion protein)§ ‡ RUBY l NCT03981796 Bintrafusp alfa, or GSK3174998 Combination with chemotherapy INTR@PID CERVICAL 046 in recurrent or primary advanced NCT04551950 INDUCE-1 l NCT02723955 Combination with other anticancer endometrial cancer Monotherapy and in combination Phase III agents in locally advanced or with pembrolizumab, dostarlimab, advanced cervical cancer cobolimab, bintrafusp alfa, Phase I GSK3174998, or chemotherapy GARNET* l NCT02715284 in advanced solid tumors Monotherapy in dMMR/MSI-H solid Phase I tumors, ovarian cancer, and NSCLC Phase I

*The trial is no longer enrolling patients with endometrial cancer. †In-license or other partnership with third party. ‡OX40 agonist antibody. §Being developed in a strategic global alliance between GSK and Merck KGaA, Darmstadt, Germany. dMMR, mismatch repair deficient; ICOS, inducible T-cell costimulator; IgG4, immunoglobulin G4; MSI-H, microsatellite instability-high; NSCLC, non-small cell lung cancer; OX40, tumor necrosis factor receptor superfamily, member 4; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; TGF-β, transforming growth factor β. This information is intended for healthcare professionals only. Compounds are investigational. Inclusion in this display does not imply regulatory approval for these compounds or indications. Information about all GSK-sponsored trials can be found at www.clinicaltrials.gov. All clinical study information updated as of January 27, 2021. ©2021 GSK group of companies or its licensor. All rights reserved. NX-GBL-NRP-OGM-210003. GL-BIN-00043. March 2021.